Intellia Therapeutics, Inc.
NTLA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $3 | $3 | $8 |
| - Cash | $0 | $0 | $1 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $3 | $2 | $8 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 59.6% | -30.4% | 57.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 82.2% | 75.3% | 85.5% | 79.2% |
| EBITDA | -$1 | -$1 | -$0 | -$0 |
| % Margin | -905.3% | -1,395.8% | -864.5% | -789.5% |
| Net Income | -$1 | -$0 | -$0 | -$0 |
| % Margin | -896.8% | -1,326.5% | -909.8% | -810.5% |
| EPS Diluted | -5.25 | -5.42 | -6.16 | -3.78 |
| % Growth | 3.1% | 12% | -63% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |